2023年6月最新SCI影响因子数据已经更新，欢迎查询！ 如果您对期刊系统有任何需求或者问题，欢迎反馈给我们。
 |
| 基本信息 | 登录收藏 | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字 | JOURNAL OF CONTROLLED RELEASE J CONTROL RELEASE （此期刊被最新的JCR期刊SCIE收录） LetPub评分 9.2
70人评分
我要评分
声誉 9.9 影响力 8.8 速度 8.8 | |||||||||||||||||
| 期刊ISSN | 0168-3659 | 微信扫码收藏此期刊 | ||||||||||||||||
| E-ISSN | 1873-4995 | |||||||||||||||||
| 2022-2023最新影响因子 （数据来源于搜索引擎） | 10.8 点击查看影响因子趋势图 | |||||||||||||||||
| 实时影响因子 | 截止2023年9月27日：6.501 | |||||||||||||||||
| 2022-2023自引率 | 5.60%点击查看自引率趋势图 | |||||||||||||||||
| 五年影响因子 | 10.2 | |||||||||||||||||
| h-index | 237 | |||||||||||||||||
| CiteScore |
| |||||||||||||||||
| 期刊简介 | The Journal of Controlled Release (JCR) publishes high-quality research articles in the broad field of delivery science and technology. This includes drug delivery systems and all aspects of formulations, such as physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development in the disciplines of pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Manuscripts that advance fundamental understanding of principles and/or demonstrate advantages of novel technologies in safety and efficacy over current clinical standards will be given priority. Each issue has the cover story highlighting the significance of a selected article published in the issue. At the end of each quarter, the JCR editors select "The Editors' Choice" from the published research articles. | |||||||||||||||||
| 期刊官方网站 | http://www.elsevier.com/wps/find/journaldescription.cws_home/502690/description#description | |||||||||||||||||
| 期刊投稿网址 | https://www.editorialmanager.com/COREL | |||||||||||||||||
| 期刊语言要求 | Language Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service. 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件，不仅能满足JOURNAL OF CONTROLLED RELEASE的语言要求，还能让JOURNAL OF CONTROLLED RELEASE编辑和审稿人得到更好的审稿体验，让稿件最大限度地被JOURNAL OF CONTROLLED RELEASE编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）帮助作者准备稿件，已助力全球15万+作者顺利发表论文。部分发表范例可查看：服务好评 论文致谢 。 提交文稿 | |||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||
| 通讯方式 | ELSEVIER SCIENCE BV, PO BOX 211, AMSTERDAM, NETHERLANDS, 1000 AE | |||||||||||||||||
| 出版商 | Elsevier | |||||||||||||||||
| 涉及的研究方向 | 医学-化学综合 | |||||||||||||||||
| 出版国家或地区 | NETHERLANDS | |||||||||||||||||
| 出版语言 | English | |||||||||||||||||
| 出版周期 | Semimonthly | |||||||||||||||||
| 出版年份 | 1984 | |||||||||||||||||
| 年文章数 | 626点击查看年文章数趋势图 | |||||||||||||||||
| Gold OA文章占比 | 10.81% | |||||||||||||||||
| 研究类文章占比： 文章 ÷（文章 + 综述） | 70.45% | |||||||||||||||||
| WOS期刊SCI分区 （ 2022-2023年最新版） | WOS分区等级：1区
| |||||||||||||||||
| 中科院《国际期刊预警 名单（试行）》名单 | 2023年01月发布的2023版：不在预警名单中 2021年12月发布的2021版：不在预警名单中 2021年01月发布的2020版：不在预警名单中 | |||||||||||||||||
| 中科院SCI期刊分区 （ 2022年12月最新升级版） | 点击查看中科院SCI期刊分区趋势图
| |||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月基础版） |
| |||||||||||||||||
| 中科院SCI期刊分区 （ 2021年12月升级版） |
| |||||||||||||||||
| 中科院SCI期刊分区 （ 2020年12月旧的升级版） |
| |||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月，原SCI撤销合并入SCIE，统称SCIE) Scopus (CiteScore) | |||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0168-3659%5BISSN%5D | |||||||||||||||||
| 平均审稿速度 | 网友分享经验： 平均2.6个月 来源Elsevier官网： 平均6.2周 | |||||||||||||||||
| 平均录用比例 | 网友分享经验： 50% | |||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍，平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务（包括SCI论文英语润色，同行资深专家修改润色，SCI论文专业翻译，SCI论文格式排版，专业学术制图等）后论文在JOURNAL OF CONTROLLED RELEASE顺利发表。
快看看作者怎么说吧：服务好评 论文致谢 | |||||||||||||||||
| 在线出版周期 | 来源Elsevier官网： 平均6.2周 | |||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | Modified CFBP-bFGF targeting to ischemic brain promoted the functional recovery of cerebral ischemia Author: Deng, Jin; Zhang, Xiaojing; Yin, Mengmeng; Cao, Wenxuan; Zhang, Bing; Liu, Qi; Hou, Xianglin; Wang, Haiping; Shi, Chunying Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 462-474. DOI: 10.1016/j.jconrel.2022.12.007 PubMed DOI |
| 2. | A tetrazine-responsive isonitrile-caged photosensitiser for site-specific photodynamic therapy Author: Xiong, Junlong; Xue, Evelyn Y.; Wu, Qianqian; Lo, Pui-Chi; Ng, Dennis K. P. Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 663-674. DOI: 10.1016/j.jconrel.2022.12.015 PubMed DOI |
| 3. | A novel peptide hydrogel of metal ion clusters for accelerating bone defect regeneration Author: Xu, Liu; Xu, Shan; Xiang, Tang Yong; Chen, Lin Wei; Zhong, Wei Xi; Zhu, Ling; Liu, Heng; Wu, Li; Li, Wei Dong; Wang, Yu Tong; Cai, Bao Chang; Yao, Jun Hong; Chen, Rui; Xin, Wen Feng; Cao, Gang; Chen, Zhi Peng Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 738-751. DOI: 10.1016/j.jconrel.2022.12.031 PubMed DOI |
| 4. | Hyaluronic acid and HA-modified cationic liposomes for promoting skin penetration and retention Author: Ni, Chang; Zhang, Zijun; Wang, Yuling; Zhang, Zhenhai; Guo, Xueping; Lv, Huixia Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 357, Issue , pp. 432-443. DOI: 10.1016/j.jconrel.2023.03.049 PubMed DOI |
| 5. | Swiss Army Knife black phosphorus-based nanodelivery platform for synergistic antiparkinsonian therapy via remodeling the brain microenvironment Author: Cheng, Guowang; Li, Zhongjun; Liu, Yujing; Ma, Rui; Chen, Xiaojia; Liu, Wen; Song, Yafang; Zhang, Yuan; Yu, Guangtao; Wu, Zhenfeng; Chen, Tongkai Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 752-766. DOI: 10.1016/j.jconrel.2022.12.024 PubMed DOI |
| 6. | Future in precise surgery: Fluorescence-guided surgery using EVs derived fluorescence contrast agent Author: Sun, Jian-Xuan; Xu, Jin-Zhou; An, Ye; Ma, Si-Yang; Liu, Chen-Qian; Zhang, Si-Han; Luan, Yang; Wang, Shao-Gang; Xia, Qi-Dong Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 832-841. DOI: 10.1016/j.jconrel.2022.12.013 PubMed DOI |
| 7. | Cell delivery devices for cancer immunotherapy Author: Wen, Ping; Wu, Wei; Wang, Feifan; Zheng, Hanqi; Liao, Ziyan; Shi, Jiaqi; Zhu, Chaojie; Zhao, Peng; Cheng, Hao; Li, Hongjun; Gu, Zhen Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 875-888. DOI: 10.1016/j.jconrel.2022.11.041 PubMed DOI |
| 8. | Surface programmed bacteria as photo-controlled NO generator for tumor immunological and gas therapy Author: Chen, Baizhu; Zhang, Xiaoge; Cheng, Lili; Chen, Xiaomei; Tang, Junjie; Zhang, Peng; Wang, Chen; Liu, Jie Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 889-902. DOI: 10.1016/j.jconrel.2022.12.030 PubMed DOI |
| 9. | 90 K increased delivery efficiency of extracellular vesicles through mediating internalization Author: Zhu, Guiquan; Yang, Fan; Wei, Hongxuan; Meng, Wanrong; Gan, Jianguo; Wang, Linlin; He, Chuanshi; Lu, Shun; Cao, Bangrong; Luo, Huaichao; Han, Bo; Li, Ling Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 930-942. DOI: 10.1016/j.jconrel.2022.12.034 PubMed DOI |
| 10. | Recruiting T cells and sensitizing tumors to NKG2D immune surveillance for robust antitumor immune response Author: Li, Xiang; Guo, Xuemeng; Huang, Jiaxin; Lin, Qing; Qin, Bing; Jiang, Mengshi; Shan, Xinyu; Luo, Zhenyu; Zhang, Junlei; Shi, Yingying; Lu, Yichao; Liu, Xu; Du, Yongzhong; Yang, Fuchun; Luo, Lihua; You, Jian Journal: JOURNAL OF CONTROLLED RELEASE. 2023; Vol. 353, Issue , pp. 943-955. DOI: 10.1016/j.jconrel.2022.12.032 PubMed DOI |
|
|
  | |
|
以上SCI期刊相关数据和信息来源于网络，仅供参考。
投稿状态统计： 我要评分： | |
同领域作者分享投稿经验：共46条 （包含回复） |
我来分享 |
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2023 中国: LetPub上海分公司 网站备案号：沪ICP备10217908号-1 
沪公网安备号：31010402006960
增值电信业务经营许可证：沪B2-20211595
礼翰商务信息咨询（上海）有限公司 办公地址：上海市徐汇区漕溪北路88号圣爱大厦2103室
United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451
安全保密
